CASA: Community-based Accompaniment With Supervised Antiretrovirals in Lima, Peru
Study Details
Study Description
Brief Summary
Using quantitative and qualitative data, this study will assess the impact of community accompaniment with supervised antiretrovirals (CASA) on HIV-positive individuals and community members in Lima, Peru.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Detailed Description
Community-based accompaniment with directly observed antiretroviral therapy (DOT-HAART) may improve adherence and clinical outcomes among impoverished individuals starting HAART in resource-poor settings. Furthermore, the utilization of community health workers may build social capital. This is cluster-randomized trial, with randomization at the level of health centers. Individuals in both intervention and control clusters will receive community-based adherence support (monthly adherence visits) and standard care. In addition, individuals residing in intervention clusters will receive 12 months of community-based DOT-HAART. We will enroll patients as well as community members (health providers, treatment supporters, and community health workers) to assess individual and community-level outcomes.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Intervention: DOT-HAART Intervention group will receive community-based monthly adherence visits, standard care, and DOT-HAART. |
Other: DOT-HAART
For 8 months, DOT-HAART of all doses in the participant's home or alternate location. DOT worker ensures that HIV medications are taken as indicated and witnesses ingestion of all medications including other medications prescribed by physician. The worker will be trained to identify, triage and notify providers of any psychosocial and medical problems/complications. Transition to self-administration begins in months 9-12 when DOT will be tapered and greater participation of treatment supporter to prepare patients for self-administration.
|
| No Intervention: No DOT-HAART Control group receives community-based monthly adherence visits and standard care, but no DOT-HAART. |
Outcome Measures
Primary Outcome Measures
- Proportion with suppressed HIV viral load after starting HAART among those receiving community-based DOT-HAART versus the control group. [18 and 24 months]
Secondary Outcome Measures
- Identify mediating mechanisms of CASA effect on individual outcomes. [24 months]
- Identify subgroups who respond best to CASA intervention. [24 months]
Eligibility Criteria
Criteria
Inclusion Criteria for Patient Cohort:
-
Age greater than or equal to 18;
-
Diagnosis if HIV and meeting criteria for HAART;
-
Lives in poverty;
-
EITHER: 1) HAART naïve or 2) starting salvage therapy due to virologic failure;
-
Documentation of baseline CD4 cell count and HIV load;
-
Residence and receipt of HIV healthcare within the study catchment area
Exclusion Criteria for Patient Cohort:
- Imprisoned or cannot give informed consent.
Inclusion Criteria for Community Cohort:
-
Working in a health establishments in study region;
-
If health personnel, contracted employee caring for people living with HIV/AIDS.
Exclusion Criteria for Community Cohort:
- Cannot give informed consent
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Socios En Salud | Lima | Peru |
Sponsors and Collaborators
- Brigham and Women's Hospital
- National Institute of Mental Health (NIMH)
- Partners in Health
- Harvard School of Public Health (HSPH)
- Harvard Medical School (HMS and HSDM)
Investigators
- Principal Investigator: Sonya Shin, MD, MPH, Brigham and Women's Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 1R01MH083550-01A2
- 1R01MH083550-01A2